论文部分内容阅读
观察尿激酶溶栓治疗急性心肌梗塞（AMI）的疗效及微循环中做血栓的变化。按WHO规定的AMI诊断标准选择病例．按1992年全国统一的溶栓方案治疗，观察溶栓前后球结膜微循环改变。对微循环中有微血栓记录溶栓前后的微血栓数量，并与溶栓结果对比分析。其中16例AMI溶栓治疗后再通者13例，再通率81．25％。溶栓前微循环中有微血栓者11例，溶栓后仅有3例。微血栓出现率由溶栓前的68．75％下降至溶栓后18．75％，统计学处理差异非常显著（p＜0．001）。13例再通者无一例再出现微血栓。可见尿激酶溶栓治疗急性心肌梗塞效果肯定，对消溶微血栓有显著作用。可把微血栓作为尿激酶治疗AMI后冠脉再通的一项辅助指标。
To observe the curative effect of urokinase thrombolytic therapy on acute myocardial infarction (AMI) and changes of thrombus during microcirculation. According to WHO diagnostic criteria for the selection of AMI cases. According to the 1992 unified national thrombolytic treatment, observe the changes of the conjunctival microcirculation before and after thrombolysis. Micro-thrombosis in the microcirculation before and after thrombolytic therapy to record the number of micro-thrombolytic and thrombolytic results were compared. Among them, 13 cases were recanalized after 16 AMI thrombolytic therapy and the recanalization rate was 81.25%. Microcirculation before thrombolysis in micro-thrombosis in 11 cases, only three cases after thrombolysis. The incidence of microthrombi decreased from 68.75% before thrombolysis to 18.75% after thrombolysis, and the difference was statistically significant (p <0.001). None of the 13 recanalization cases showed microthrombus again. Visible urokinase thrombolytic treatment of acute myocardial infarction positive effect on the dissolution of micro-thrombosis have a significant role. Micro-thrombus can be used as a urokinase after AMI coronary recanalization as a secondary indicator.